Curis (CRIS) director receives Series B preferred and multi-series warrant grants

Rhea-AI Filing Summary

CURIS INC director Marc Rubin reported grants of new preferred stock and warrants linked to common shares. On March 17, 2026, he received 20 shares of Series B Convertible Preferred Stock, which automatically convert into 26,667 shares of common stock for no additional payment at 5 p.m. Eastern Time on March 20, 2026, subject to stated beneficial ownership limits.

He was also granted Series A, Series B and Series C warrants, each for 26,667 common shares at an exercise price of $0.75 per share. The Series A and Series C warrants became immediately exercisable upon receipt of required stockholder approval and a certificate of amendment filing, while the Series B warrants are exercisable on similar conditions but have a termination date tied to dosing milestones in a Phase 2 clinical trial and may have their exercise price reset and term extended based on the stock price at that milestone.

Insights

Equity compensation analyst

Director received structured equity grants, not open‑market purchases or sales.

Director Marc Rubin acquired a package of preferred stock and warrants that can translate into common shares over time. The grants include 20 Series B preferred shares automatically converting into 26,667 common shares and three warrant series each covering 26,667 shares at $0.75.

These are compensation-type awards (code A) rather than discretionary market trades, so they mainly increase his potential equity exposure. The Series B warrants’ term and pricing are linked to a Phase 2 emavusertib trial milestone, tying part of the upside to clinical progress and the stock price at that dosing event.

Overall, this looks like routine incentive structuring for a director, using preferred stock and milestone-based warrants instead of simple restricted stock. Future company filings may show how much of this derivative exposure he ultimately exercises as milestones are reached.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Marc

(Last) (First) (Middle)

128 SPRING STREET

BUILDING C - SUITE 500

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CURIS INC [ CRIS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Convertible Preferred Stock	(1)	03/17/2026		A		20		(1)	(1)	Common Stock	26,667	(2)	20	D
Series A Warrant (right to buy)	$0.75	03/17/2026		A		26,667		(3)	01/08/2031	Common Stock	26,667	(2)	26,667	D
Series B Warrant (right to buy)	$0.75(4)	03/17/2026		A		26,667		(4)	(4)	Common Stock	26,667	(2)	26,667	D
Series C Warrant (right to buy)	$0.75	03/17/2026		A		26,667		(5)	07/08/2027	Common Stock	26,667	(2)	26,667	D

Explanation of Responses:

1. Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).

2. Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.

3. Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026.

4. The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.

5. The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026.

Remarks:

	/s/ Diantha Duvall, Attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Curis (CRIS) director Marc Rubin acquire in this Form 4?

Marc Rubin received equity-based awards, not open-market trades. He was granted Series B convertible preferred stock and Series A, B, and C warrants, each series linked to 26,667 Curis common shares, expanding his potential ownership if the instruments convert or are exercised.

How many Curis common shares are tied to Marc Rubin’s new preferred stock grant?

The grant includes 20 shares of Series B Convertible Preferred Stock. Each preferred share automatically converts into 1,333.33 common shares, totaling 26,667 Curis common shares, with conversion scheduled at 5 p.m. Eastern Time on March 20, 2026, subject to stated beneficial ownership limitations.

What are the key terms of Marc Rubin’s Curis warrant grants?

He received Series A, B, and C warrants, each covering 26,667 Curis common shares at an exercise price of $0.75 per share. The Series A and C warrants became immediately exercisable after specific stockholder approvals and corporate filings, while Series B warrants include milestone-based termination and potential exercise price reset.

How does the Curis Series B Warrant granted to Marc Rubin work?

The Series B Warrant became exercisable after required approvals and will terminate 30 days after Curis announces the fifth patient dosed in a Phase 2 emavusertib trial. If the stock price is below $0.75 then, the exercise price may reset and the term extend another 30 days within defined limits.

Are Marc Rubin’s Curis equity awards open-market purchases or compensation grants?

They are compensation-type grants, coded as awards or other acquisitions rather than market buys. The preferred stock and warrant positions were provided at no cash exercise on grant, with potential future costs only if warrants are exercised at the $0.75 per share exercise price.

When do Marc Rubin’s Series A and Series C Curis warrants become exercisable?

Both Series A and Series C Warrants became immediately exercisable on March 17, 2026. This followed receipt of the defined Requisite Stockholder Approval and the related Certificate of Amendment filing, as specified in the individual warrant terms for each series.